Keen Vision Acquisition CorpKVAC
KVAC
About: Keen Vision Acquisition Corp is a blank check company.
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2% more capital invested
Capital invested by funds: $136M [Q2] → $139M (+$2.56M) [Q3]
0% more funds holding
Funds holding: 37 [Q2] → 37 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.34% less ownership
Funds ownership: 66.41% [Q2] → 66.08% (-0.34%) [Q3]
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for KVAC.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements This new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platform Innovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation drug classification capabilities The unique combination of AI/ML and human mini-Hearts can accelerate drug discovery, clinical translation and precision medicine by improving screening efficiency, reducing costs, enhancing safety and creating new opportunities for patient benefits SUMMIT, N.J. and BOSTON, Mass.
Neutral
PRNewsWire
1 month ago
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics Promising efficacy results in cardiovascular performance observed in Cohort A (low-dose SRD-002) at six months with additional data being collected Initiated dosing patients in Cohort B (high-dose SRD-002) following recommendation of the DSMB SUMMIT, N.J. and BOSTON , Oct. 24, 2024 /PRNewswire/ -- Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-dose).
Neutral
PRNewsWire
3 months ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisition Corp. - KVAC
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
Neutral
PRNewsWire
3 months ago
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms Transaction proceeds to accelerate three most advanced clinical programs for the adeno-associated virus (AAV)-based gene therapy candidates The combined company to have an implied initial enterprise value of approximately $622.6 million Medera's founders and key shareholders have committed approximately $22.6 million (via conversion of all shareholders loans) for this merger, with all existing Medera shareholders rolling 100% of their equity As a closing condition to the business combination, Medera shall have at least $40 million in available liquidity Anticipated closing of transaction in fourth quarter of 2024 SUMMIT, N.J. and BOSTON , Sept.
Charts implemented using Lightweight Charts™